Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Safety and Efficacy of IDP-122 in Participants With Plaque Psoriasis

ClinicalTrials.gov ID: NCT02515097

Public ClinicalTrials.gov record NCT02515097. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 1:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is to evaluate the safety and efficacy of a topical lotion when applied once daily to adult participants with moderate to severe plaque psoriasis (defined as an Investigator's Global Assessment \[IGA\] score of 3 or 4).

Study identification

NCT ID
NCT02515097
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Bausch Health Americas, Inc.
Industry
Enrollment
213 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 5, 2015 (Actual)
Primary completion
Mar 15, 2017 (Actual)
Completion
Mar 15, 2017 (Actual)
Last update posted
Oct 20, 2026

2015 – 2017

United States locations

U.S. sites
15
U.S. states
11
U.S. cities
15
Facility City State ZIP Site status
Valeant Site 14 Santa Ana California 92701 —
Valeant Site 02 Boynton Beach Florida 33424 —
Valeant Site 10 Clearwater Florida 33755 —
Valeant Site 1 Tampa Florida 33603 —
Valeant Site 07 Plainfield Indiana 46168 —
Valeant Site 15 Olathe Kansas 66051 —
Valeant Site 08 Fridley Minnesota 55421 —
Valeant Site 13 Omaha Nebraska 68022 —
Valeant Site 04 New York New York 10001 —
Valeant Site 12 Stony Brook New York 11790 —
Valeant Site 05 High Point North Carolina 27260 —
Valeant Site 11 Knoxville Tennessee 37901 —
Valeant Site 03 Houston Texas 77001 —
Valeant Site 09 San Antonio Texas 78201 —
Valeant Site 06 West Jordan Utah 84081 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02515097, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 20, 2026 · Synced Oct 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02515097 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →